PFE (Pfizer Inc.) Stock Financials & Earnings | Market Cap Arena

Market CapArena

PFE (Pfizer Inc.) Stock Financials & Earnings | Market Cap Arena

NEW

PFEPfizer Inc.

Mkt Cap$152B

PFEPfizer Inc.

$152B

NEW

Company Info & Key Metrics

Healthcare Drug Manufacturers - General

Country🇺🇸 United States

ExchangeNYSE

Revenue$17.6B

YoY Growth-1.2%

QoQ Growth+5.4%

Net Income-$1.6B

EPS-$0.29

Free Cash Flow$4.5B

Gross Margin70.0%

Op. Margin21.0%

Net Margin-9.4%

FCF Margin25.6%

Rev Multiple (TTM)2.4x

P/E Ratio (TTM)19.6x

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$18.5B	$12.5B	$6.7B
Q2 23	$13.0B	$8.4B	$2.4B
Q3 23	$13.5B	$2.9B	-$3.0B
Q4 23	$14.6B	$6.0B	-$1.3B
Q1 24	$14.9B	$10.5B	$4.6B
Q2 24	$13.3B	$8.2B	$1.9B
Q3 24	$17.7B	$10.8B	$5.0B
Q4 24	$17.8B	$13.0B	$5.7B
Q1 25	$13.7B	$9.8B	$4.6B
Q2 25	$14.7B	$9.4B	$3.6B
Q3 25	$16.7B	$12.5B	$3.5B
Q4 25	$17.6B	$12.3B	$3.7B

Valuation

Quarter	P/S	P/E
Q1 23	1.6x	5.3x
Q2 23	1.9x	7.1x
Q3 23	2.2x	14.6x
Q4 23	2.6x	71.4x
Q1 24	2.7x	—
Q2 24	2.7x	—
Q3 24	2.5x	35.7x
Q4 24	2.4x	19.0x
Q1 25	2.4x	19.4x
Q2 25	2.4x	14.2x
Q3 25	2.4x	15.5x
Q4 25	2.4x	19.6x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	$1.2B	$74M
Q2 23	-$1.2B	-$2.1B
Q3 23	$3.5B	$2.6B
Q4 23	$5.2B	$4.2B
Q1 24	$1.1B	$386M
Q2 24	-$1.8B	-$2.4B
Q3 24	$6.7B	$6.1B
Q4 24	$6.7B	$5.8B
Q1 25	$2.3B	$1.8B
Q2 25	-$582M	-$1.2B
Q3 25	$4.6B	$4.0B
Q4 25	$5.3B	$4.5B

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$1.1B
Q2 23	$914M
Q3 23	$810M
Q4 23	$1.0B
Q1 24	$704M
Q2 24	$637M
Q3 24	$651M
Q4 24	$917M
Q1 25	$564M
Q2 25	$618M
Q3 25	$602M
Q4 25	$845M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-28.0%	-24.4%
Q2 23	-53.1%	-28.0%
Q3 23	-40.4%	+27.5%
Q4 23	-40.0%	-16.4%
Q1 24	-19.5%	-12.5%
Q2 24	+2.1%	+7.0%
Q3 24	+31.2%	-22.8%
Q4 24	+21.9%	-24.0%
Q1 25	-7.8%	-11.9%
Q2 25	+10.3%	-2.9%
Q3 25	-5.9%	+2.9%
Q4 25	-1.2%	+15.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$105M	0.6%
Q2 23	$148M	1.1%
Q3 23	$151M	1.1%
Q4 23	$121M	0.8%
Q1 24	$220M	1.5%
Q2 24	$206M	1.6%
Q3 24	$274M	1.5%
Q4 24	$177M	1.0%
Q1 25	$170M	1.2%
Q2 25	$203M	1.4%
Q3 25	$201M	1.2%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 23	$2.5B	$3.4B
Q2 23	$2.6B	$3.4B
Q3 23	$2.7B	$3.2B
Q4 23	$2.8B	$4.5B
Q1 24	$2.5B	$3.5B
Q2 24	$2.7B	$3.7B
Q3 24	$2.6B	$3.2B
Q4 24	$3.0B	$4.2B
Q1 25	$2.2B	$3.0B
Q2 25	$2.4B	$3.4B
Q3 25	$3.9B	$3.2B
Q4 25	$3.4B	$3.7B

Revenue Segments

Quarter	Biopharma Segment	Business Innovation Segment
Q1 23	$18.0B	$310M
Q2 23	$12.4B	$316M
Q3 23	$12.9B	$302M
Q4 23	$13.9B	$382M
Q1 24	$14.6B	$275M
Q2 24	$13.0B	—
Q3 24	$17.4B	—
Q4 24	$17.4B	—
Q2 25	$14.3B	—
Q3 25	$16.3B	—

Revenue by Geography

Quarter	Developed Europe	Developed Rest Of World	Emerging Markets	United States
Q1 23	$2.8B	$2.5B	$4.5B	$8.5B
Q2 23	$2.4B	$1.3B	$2.8B	$6.2B
Q3 23	$2.0B	$1.1B	$2.4B	$7.8B
Q4 23	$4.4B	$2.9B	$2.3B	$4.6B
Q1 24	—	$3.2B	$2.2B	$9.5B
Q2 24	—	$3.2B	$2.2B	$7.9B
Q3 24	—	$3.4B	$2.2B	$12.1B
Q4 24	—	$6.3B	$2.3B	$9.2B
Q2 25	—	$3.4B	$2.4B	$8.9B
Q3 25	—	$3.7B	$2.3B	$10.7B

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$2.2B	$17.8B	$20.0B
Q2 23	$2.6B	$42.2B	$44.8B
Q3 23	$3.1B	$41.0B	$44.2B
Q4 23	$2.9B	$9.8B	$12.7B
Q1 24	$719M	$11.2B	$11.9B
Q2 24	$1.1B	$6.0B	$7.1B
Q3 24	$1.1B	$8.9B	$10.0B
Q4 24	$1.0B	$19.4B	$20.5B
Q1 25	$1.4B	$15.9B	$17.3B
Q2 25	$1.6B	$11.6B	$13.2B
Q3 25	$1.3B	$13.6B	$15.0B
Q4 25	$1.1B	$12.5B	$13.6B

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	5.73B	-0.3%
Q2 23	5.71B	-0.2%
Q3 23	5.65B	-1.2%
Q4 23	5.65B	+0.0%
Q1 24	5.70B	+0.9%
Q2 24	5.70B	-0.0%
Q3 24	5.71B	+0.2%
Q4 24	5.70B	-0.0%
Q1 25	5.71B	+0.1%
Q2 25	5.71B	-0.1%
Q3 25	5.71B	+0.1%
Q4 25	5.69B	-0.5%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$634K	78K
FY 15	$499K	98K
FY 16	$547K	97K
FY 17	$583K	90K
FY 18	$581K	92K
FY 19	$466K	88K
FY 20	$531K	79K
FY 21	$1M	79K
FY 22	$1M	83K
FY 23	$677K	88K
FY 24	$786K	81K
FY 25	$834K	75K